October 4, 2022

Medical Trend

Medical News and Medical Resources

What are differences between Mirati’s Adagrasib and Amgen’s Lumakras?

What are differences between Mirati’s Adagrasib and Amgen’s Lumakras?



 

What are differences between Mirati’s Adagrasib and Amgen’s Lumakras?

 

As the biggest competitor of Amgen‘s KRAS inhibitor Lumakras , Mirati Therapeutics ‘ Adagrasib is far behind the other in the time to market and urgently needs excellent data from a clinical study. Now it seems that the dream may be dashed.

 

What are differences between Mirati's Adagrasib and Amgen's Lumakras?

What are differences between Mirati's Adagrasib and Amgen's Lumakras?

 

On May 26 , Mirati announced results from a new Phase II KRYSTAL-1 cohort study of its KRAS inhibitor adagrasib, evaluating adagrasib 600 mg BID in patients with KRASG12C – mutated non-small cell lung cancer (NSCLC) who At least one prior systemic therapy.

 

As of October 15 , 2021 , a total of 116 patients were enrolled and treated. Of the enrolled patients, 98% had received PD-1/L1 inhibitor therapy after chemotherapy or in combination with chemotherapy , and the median follow-up time was 12.9 months.

 

Among patients with evaluable response ( n=112 ), preliminary results showed an objective response rate ( ORR ) of 43% by blinded independent central review ( BICR ) , disease control rate ( DCR ) of 80% , and median duration of response ( DOR ) was 8.5 months and median progression-free survival ( PFS ) was 6.5 months.

 

The data cutoff was January 15 , 2022 , and the median overall survival (OS) was 12.6 months.

 

Study results to be presented June 3 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

 

Mirati appeared to get what it needed for its efficacy, with an objective response rate of 43% in non-small cell lung cancer, compared with 37% for Amgen ‘s approved drug Lumakras .

 

But the question is how long the effect lasts. In this regard, Amgen appears to be winning.

 

Lumakras documented the lower objective response rate in data presented at last year ‘s ASCO meeting from 124 patients who had previously received platinum-based chemotherapy and immunotherapy.

But response duration for Lumakras was more than two and a half months longer than adagrasib , at 11.1 months ; the disease control rate was also 80% .

 

In terms of overall survival , as of Jan. 15, adagrasib was 12.6 months , just slightly ahead of Lumakras ‘ 12.5 months .

 

The latest adagrasib data did not appear to have a clear advantage over Lumakras, causing Mirati ‘s shares to plunge 32% to $ 39.73 in premarket trading on May 27 , compared with the previous close of $ 58.46 .

 

Amgen’s Lumakras (sotorasib) was approved by the FDA in May last year , becoming the first KRAS inhibitor approved in the world, and has also been approved in Europe and Japan.

 

If Mirati can provide better efficacy or treatment responsiveness data for adagrasib, there should be an opportunity to close the gap with Lumakras . Now, those hopes appear to be dashing.

 

adagrasib is currently seeking listing in Europe and the United States. In addition to the time gap with Lumakras , Mirati may be more worried about the future market.

 

 

 

What are differences between Mirati’s Adagrasib and Amgen’s Lumakras?

(source:internet, reference only)


Disclaimer of medicaltrend.org